Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.

Abstract excerpt

The European Society for Medical Oncology defines rare cancers as 5 or fewer cases per 100,000 persons per year. For many rare cancers, no standard of care exists, and treatment is often extrapolated. Identifying potentially targetable genomic alterations in rare tumors is a rational approach to improving treatment options. We sought to catalog these mutations in rare tumors and to assess their clinical...

Topics

Join the communities discussing this publication.

• High-Throughput Nucleotide Sequencing
• Medical Oncology
• Molecular Targeted Therapy
• Neoplasm Proteins
• Neoplasms